Orion Oyj (FRA:OFK)

Market Cap	9.26B
Revenue (ttm)	1.63B
Net Income (ttm)	313.20M
Shares Out	n/a
EPS (ttm)	2.23
PE Ratio	29.56
Forward PE	18.74
Dividend	1.64 (2.60%)
Ex-Dividend Date	Oct 15, 2025

Volume	n/a
Average Volume	1
Open	63.10
Previous Close	63.85
Day's Range	63.10 - 63.20
52-Week Range	42.97 - 71.75
Beta	n/a
RSI	68.11
Earnings Date	Feb 12, 2026

About Orion Oyj

Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. The company provides pharmaceutical products, which includes Nubeqa for the treatment of prostate cancer; Entacapone, Stalevo, Comtess, and Comtan to treat Parkinson's disease; Burana for inflammatory pain; Divina series for menopausal symptoms; Simdax for acute decompensated heart failure; Fareston for breast cancer; Trexan for rheumatoid art...

• Industry: Pharmaceutical Preparations
• Founded: 1917
• Employees: 3,880
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: OFK

Financial Performance

In 2024, Orion Oyj's revenue was 1.54 billion, an increase of 29.65% compared to the previous year's 1.19 billion. Earnings were 329.90 million, an increase of 52.17%.